Ascites is the most common complication of cirrhosis and often marks the shift from compensated to decompensated disease. It can reduce quality of life, prompt hospitalizations, and increase the risk of infections and kidney complications. Five-year survival falls from about 80% to 30% after clinically significant ascites develops. Treatment therefore aims to control fluid buildup while preventing complications and preserving kidney and circulatory function.
Addressing this challenge, the research team was led by Professor Paolo Caraceni, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy. In this narrative review, the authors examined relevant studies identified through PubMed from its inception to June 2026, alongside findings presented at major international congresses. They assessed human albumin use across clinical settings, distinguishing short-term treatment for acute complications from regular infusions intended to improve longer-term ascites control. The study was published online in the journal Portal Hypertension & Cirrhosis on November 13, 2026.
Albumin is a blood protein used to expand plasma volume and counteract reduced effective circulating blood volume. It may also support blood-vessel function and modulate inflammation. The review describes three established short-term settings: after large-volume paracentesis; during spontaneous bacterial peritonitis; and in acute kidney injury, including hepatorenal syndrome. For removal of more than 5 L of fluid, international guidelines generally recommend 6–8 g of albumin per liter removed.
Albumin use in kidney injury remains debated. A 2024 joint consensus advised volume resuscitation when clinically indicated rather than routinely. Subsequent studies suggest some patients respond only on the second day, while excessive fluid administration may increase the risk of respiratory complications. The review emphasizes tailoring dose and duration to the patient's condition and stopping treatment if fluid overload develops.
For longer-term treatment, evidence is promising but inconsistent. In the ANSWER trial, 431 patients with uncomplicated grade 2 or 3 ascites received standard treatment alone or with albumin: 40 g twice weekly for 2 weeks, then 40 g weekly for up to 18 months. The albumin group had higher 18-month survival and a 38% reduction in mortality risk, alongside fewer paracenteses and complications. By contrast, the MACHT trial found no significant benefit, but used a lower dose and the treatment was often shorter. Studies from Italy, Australia, and India add evidence, while PRECIOSA did not meet its primary endpoint of improved 1-year transplant-free survival.
"Albumin should not be viewed as a universal treatment for every person with cirrhosis and ascites," says Prof. Caraceni. "The evidence points to benefits in specific situations, but the patient's clinical condition, treatment schedule, and response all matter."
The review also discusses preliminary evidence that albumin may help some patients with hypervolemic hyponatremia, although larger studies are needed. Better ways to identify likely responders, including biomarker-based approaches, could help guide treatment. This may support more personalized treatment strategies and help health systems assess cost-effectiveness, logistical barriers, and delivery options such as home infusions.
"Ultimately, we need to move beyond a one-size-fits-all approach and match albumin treatment to the patient's needs and goals," says Prof. Caraceni.
Overall, the review concludes that albumin remains an important option for managing cirrhosis-related ascites, but its value depends on selecting appropriate patients and individualizing treatment. Better evidence on who benefits, at what dose, and for how long will be essential to improve care and guide wider use.